Core Insights - AtaiBeckley Inc. is advancing its clinical-stage biotechnology efforts, particularly focusing on BPL-003, a nasal spray for treatment-resistant depression (TRD), with plans to initiate Phase 3 studies in Q2 2026 following a successful End-of-Phase 2 meeting with the FDA [1][4][5] Clinical Development - BPL-003 has received Breakthrough Therapy Designation and has shown positive Phase 2b results, indicating rapid antidepressant effects by Day 2 and sustained improvements for up to eight weeks [2][8] - The upcoming Phase 3 studies, ReConnection-1 and ReConnection-2, will consist of a 12-week randomized, double-blind, placebo-controlled core study, followed by a 52-week open-label extension [4][5] Financial and Operational Readiness - The company has reaffirmed its cash runway extending into early 2029, ensuring financial stability for ongoing and future clinical trials [3][7] - AtaiBeckley is advancing its commercial readiness strategy for BPL-003, aiming to integrate the treatment into existing psychiatric workflows without the need for in-session psychotherapy [5][6] Pipeline Progress - The company is also making progress with other pipeline candidates, including positive Phase 2a results for EMP-01 and anticipates topline data for VLS-01 in H2 2026 [3][7] Expert Perspectives - Discussions during the Investor Day highlighted the importance of streamlined treatment experiences and the potential for BPL-003 to expand patient access while maintaining clinical efficacy [9][10]

Core Viewpoint - GH Research PLC has reported significant progress in its clinical development of GH001 for treatment-resistant depression (TRD), with promising Phase 2b trial results and a strong financial position as of the end of 2025 [1][2][5]. Business Update - The company completed its Phase 2b trial of GH001 in TRD and presented the full dataset at major conferences in 2025 [2]. - GH Research is seeking FDA alignment for its global Phase 3 pivotal program, which aims to replicate the Phase 2b study [2]. Clinical Trial Results - The Phase 2b trial achieved its primary endpoint with a placebo-adjusted Montgomery-Åsberg Depression Rating Scale (MADRS) reduction of -15.5 points at Day 8 (p<0.0001) [3]. - 57.5% of patients on GH001 achieved remission (MADRS ≤10) at Day 8 compared to 0% on placebo [3]. - The open-label extension showed a 73% remission rate at six months with infrequent retreatment visits and no mandated psychotherapy [3]. - Safety results were favorable, with no treatment-related serious adverse events reported [3]. Financial Highlights - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $280.7 million, up from $182.6 million in 2024 [5]. - Research and development expenses increased to $38.8 million in 2025 from $35.0 million in 2024, primarily due to technical development and employee expenses [6]. - General and administrative expenses rose to $22.0 million in 2025 from $15.3 million in 2024, driven by increased professional fees and employee expenses [7]. - The net loss for 2025 was $48.3 million, or $0.79 per share, compared to a net loss of $39.0 million, or $0.75 per share, in 2024 [8]. Product Development - GH001 is formulated for mebufotenin administration via a proprietary inhalation approach, with the potential to change TRD treatment [10]. - The company is also developing GH002, a mebufotenin product candidate for intravenous administration, having completed a Phase 1 trial in healthy volunteers [11].

Ultra-Rapid, Durable Remission in TRD with Minimal Clinic Burden GH Research PLC (Nasdaq: GHRS) March 2026 2026© GH Research PLC 1 Disclaimer Regarding Forward-Looking Statements This presentation has been prepared by GH Research PLC ("GH Research"). Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or GH Research or any director, employee, agent, or adviser of GH Research. This presentation does not purport to be all-inclusive ...

Core Insights - Compass Pathways plc has received FDA acceptance for its IND application for COMP360, allowing the start of a late-stage clinical trial for PTSD [1][5] - The company aims to address the significant unmet need in PTSD and treatment-resistant depression (TRD) through innovative therapies [2][14] Late-Stage Clinical Trial for PTSD - The Phase 2b/3 clinical trial (COMP202) will evaluate the efficacy, safety, and tolerability of COMP360 in PTSD patients [5] - The trial consists of two parts: a 12-week blinded study comparing two doses of COMP360 (25 mg vs. 1 mg) and a 40-week open-label follow-up [5] - The primary efficacy endpoint is the change in CAPS-5 total severity score at Week 8 [5] Commercialization Readiness in TRD - Compass is preparing for the commercialization of COMP360 for TRD, with a focus on ensuring patient access if approved [2][12] - The company has had positive discussions with the FDA regarding its NDA submission strategy for COMP360 in TRD, including potential rolling submission scenarios [5] - The company has also expanded its collaborations to enhance the integration of COMP360 into healthcare settings [5] Financial Updates - Compass has amended its term loan facility with Hercules Capital, increasing it to $150 million, with $50 million already drawn [12] - The amendment extends the interest-only period until at least January 2029, providing financial flexibility [12] About PTSD and TRD - PTSD affects approximately 13 million adults in the U.S. annually, with limited treatment options available [10][8] - TRD impacts around 4 million patients in the U.S., characterized by inadequate response to multiple treatments [13]

Core Insights - Compass Pathways plc is hosting a webinar on January 7, 2026, to discuss its commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress disorder (PTSD) [1] - The webinar will feature discussions on patient care pathways, provider economics for multi-hour treatments, and treatment model development in TRD [2][3] - The management team will review commercial readiness activities and the emerging profile of COMP360 in TRD, highlighting the unmet need in PTSD and detailing the planned late-stage program for COMP360 in this indication [3] Company Overview - Compass Pathways is a biotechnology company focused on accelerating patient access to evidence-based innovations in mental health, particularly for those with serious mental health conditions not adequately addressed by existing treatments [5] - The company is pioneering a new treatment paradigm with its investigational COMP360 synthetic psilocybin treatment, which has received Breakthrough Therapy designation from the FDA and Innovative Licensing and Access Pathway designation in the UK for TRD [5] Webinar Details - The webinar will include perspectives from key opinion leaders (KOLs) and industry leaders on the current treatment landscape and the significant unmet needs in TRD and PTSD [3] - Speakers at the event will include notable figures in the field of psychiatry and mental wellness [7]

Summary of COMPASS Pathways FY Conference Call Company Overview - **Company**: COMPASS Pathways (NasdaqGS:CMPS) - **Focus**: Development of COMP360 for treatment-resistant depression (TRD) and potential expansion into PTSD Key Industry Insights - **Psychedelic Industry Trends**: The FDA is currently reviewing a significant number of psychedelic treatments, with more than half of their reviews focused on psychedelics [1][3] - **Market Landscape**: Approximately 6,000 treatment centers are currently administering Spravato, with a growth rate of 35%-40% year-over-year [15][17] Core Points and Arguments - **FDA Interactions**: The company is in discussions with the FDA regarding a rolling NDA submission for COMP360, with a potential submission timeline in late 2026 [3][7] - **Clinical Trials**: The primary endpoint data from the second phase 3 study (COMP006) is expected to be disclosed in Q1 2026, which is crucial for the NDA submission [3][104] - **Commercial Strategy**: The launch strategy will focus on existing Spravato treatment centers, leveraging the same healthcare professionals [19][21] - **Sales Force Structure**: The sales force will be smaller than traditional antidepressant launches due to the limited number of prescribers for Spravato [36][38] - **Efficacy Comparison**: COMP360 aims to achieve similar efficacy to Spravato with significantly fewer treatments (one treatment vs. ten for Spravato) [43][87] - **Payer Access**: The company anticipates favorable formulary access due to the lack of other proven pharmacologic options for TRD [51][53] Important but Overlooked Content - **Safety Profile**: The most common side effects reported in trials were mild to moderate, with no new safety signals identified [130][136] - **PTSD Program**: A phase 2 open-label study showed over 80% remission in PTSD patients, with plans for a registrational study to begin in Q1 2026 [164][170] - **Future Indications**: While currently focused on TRD, the company acknowledges potential future opportunities in other psychiatric conditions such as OCD and bipolar II [186][192] Conclusion COMPASS Pathways is strategically positioned in the psychedelic treatment landscape, with a strong focus on TRD and emerging opportunities in PTSD. The company's proactive engagement with the FDA and its commercial readiness plans indicate a robust approach to market entry and patient access.

Core Insights - GH Research PLC reported financial results for Q3 2025, highlighting advancements in their treatment for depression and ongoing engagement with the FDA regarding their Investigational New Drug Application for GH001 [1][2]. Business Updates - GH001 Update: The company is addressing the last remaining topic from the FDA's clinical hold on their IND for GH001, with ongoing communication with the FDA [2]. - Phase 2b TRD Data: The full dataset from the Phase 2b clinical trial of GH001 in treatment-resistant depression (TRD) was reported, showing a significant reduction in depression scores [3][12]. - Remission Rate: The trial confirmed a 73% remission rate at 6 months with no serious adverse events reported during the trial [4][5]. Financial Highlights - Cash Position: As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $293.9 million, an increase from $182.6 million at the end of 2024 [7][17]. - R&D Expenses: Research and development expenses for Q3 2025 were $10.6 million, up from $8.4 million in Q3 2024, primarily due to increased technical development costs [7][9]. - G&A Expenses: General and administrative expenses rose to $6.0 million in Q3 2025 from $4.2 million in Q3 2024, attributed to higher professional fees and employee expenses [10]. - Net Loss: The net loss for Q3 2025 was $14.0 million, or $0.23 per share, compared to a loss of $12.1 million, or $0.23 per share, in the same quarter of 2024 [10][16].

COMP360 Clinical Development - The company is accelerating commercialization launch readiness plans by 9-12 months[5] - COMP360 psilocybin treatment has the potential to deliver rapid, durable, and meaningful improvements[5] - Phase 2b results demonstrated significant, rapid, and durable antidepressant effects[5] - Phase 3 COMP005 trial achieved its primary endpoint with high statistical significance, showing a clinically-meaningful mean treatment difference of -3.6 points on the MADRS scale (p<0.001)[16, 20] - Long-term data from COMP004 shows average efficacy of a single dose of 25mg COMP360 at 92 days[28] Market and Financial Position - Approximately 3 million U S patients suffer from Treatment-Resistant Depression (TRD), representing a large unmet need in psychiatry[5] - An estimated 13 million adults in the U S are affected by PTSD each year, with limited effective treatment options[5] - The company had $185.9 million in cash as of September 30, 2025, providing sufficient runway into 2027[5] Commercialization Strategy - The company's early commercial planning efforts are focused on ensuring appropriate TRD patients can access COMP360, if approved[32] - Potential launch of COMP360 will leverage a well-established infrastructure of interventional psychiatry treatment centers, including approximately 6,000 Spravato treatment centers in the U S[33] TRD Market - Approximately 21 million U S adults experience major depression each year[7] - Approximately 9 million MDD patients have failed by ≥2 antidepressants and are considered TRD[7] - Spravato® (J&J) is guided to become a $3 - $3.5B product by 2028, many TRD patients remain unresponsive or intolerant to current therapies[5]

Transforming Mental Health Care Investor Presentation February 2025 Disclaimer Cautionary Note Regarding Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, you can identify forward-looking statements by terms such as "believe," "continue," "could," "estimate," "expect," "may," "might," "plan," "potential," "project," "should," "target," "will," "would," or the negative of th ...

Core Insights - GH Research PLC reported financial results for the year ended December 31, 2024, and provided updates on its clinical programs and financial position [1] Business Updates - GH001, an inhalable mebufotenin product candidate, is in a Phase 2b trial for treatment-resistant depression (TRD) involving approximately 80 patients [2] - The trial met its primary endpoint with a significant placebo-adjusted reduction of -15.5 in the Montgomery-Åsberg Depression Rating Scale (MADRS) on Day 8 (p<0.0001) [3] - A 57.5% remission rate was observed in patients treated with GH001 on Day 8 compared to 0% in the placebo group (p<0.0001) [3] - Safety analysis for the ongoing open-label extension (OLE) has not been completed, but as of January 22, 2025, 77.8% of OLE completers were in remission at the 6-month visit [4] - The Phase 1 trial for the proprietary aerosol delivery device is ongoing in the UK [5] Regulatory Updates - The Investigational New Drug Application (IND) for GH001 was placed on clinical hold by the FDA, which requested additional inhalation toxicology studies and device design verification [6] - The company has completed the requested inhalation toxicology studies, showing no adverse findings in the respiratory tract of dogs [7][9] - A full response to the IND hold is on track for submission in mid-2025 [10] Clinical Trials - Two Phase 2a proof-of-concept trials for GH001 in postpartum depression (PPD) and bipolar II disorder (BDII) have been completed [11] - The PPD trial met its primary endpoint with a MADRS reduction of -35.4 points (96.3%) on Day 8, with 100% of patients in remission [12] - The BDII trial also met its primary endpoint with a MADRS reduction of -16.8 points (51.9%) on Day 8, with 33.3% of patients in remission [13] Financial Highlights - As of December 31, 2024, the company had cash, cash equivalents, and marketable securities totaling $182.6 million, down from $222.7 million in 2023 [14] - Research and development expenses increased to $35.0 million in 2024 from $29.8 million in 2023, primarily due to clinical development activities [15] - General and administrative expenses rose to $15.3 million in 2024 from $11.4 million in 2023, driven by higher professional fees and increased headcount [16] - The net loss for 2024 was $39.0 million, or $0.75 loss per share, compared to a net loss of $35.6 million, or $0.68 loss per share, in 2023 [17]